New Haven, Connecticut
Cancer clinical trials in New Haven, CT
183 cancer studies are recruiting participants at sites in New Haven as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
New Haven at a glance
- 183 studies are recruiting at a site in New Haven.
- By phase: Phase 1 (39), Phase 1/2 (34), Phase 2 (38), Phase 2/3 (3), Phase 3 (46), Phase 4 (1), No phase (9), Observational (13). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (102), university, hospital or other (71), government (10).
- By research area: Breast Cancer (65), Lung Cancer (47), Lymphoma (37), Prostate Cancer (18), Pancreatic Cancer (10), Melanoma (6).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in New Haven
Basic details from each study's public record (the 30 most recently updated of 183). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study site
- Yale University School of Medicine
- Registry record
- NCT06324357 · updated
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Study site
- Yale University - Yale University School of Medicine
- Registry record
- NCT07360314 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Yale University
- Registry record
- NCT06058377 · updated
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Stemline Therapeutics, Inc.
- Study site
- Yale Comprehensive Cancer Center
- Registry record
- NCT06638307 · updated
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- Yale Cancer Center
- Registry record
- NCT07222267 · updated
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- Smilow Cancer Hospital - Yale New Haven Health · Smilow Cancer Hospital Phase 1 Unit · Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP
- Registry record
- NCT04557449 · updated
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- Yale Cancer Center
- Registry record
- NCT07503808 · updated
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- Smilow Cancer Center/Yale-New Haven Hospital · Yale University
- Registry record
- NCT03723928 · updated
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- ORIC Pharmaceuticals
- Study site
- Yale Cancer Center
- Registry record
- NCT05315700 · updated
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Yale Cancer Center ( Site 0053)
- Registry record
- NCT06393374 · updated
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Relay Therapeutics, Inc.
- Study site
- Yale-New Haven Hospital-Yale Cancer Center
- Registry record
- NCT06982521 · updated
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- NiKang Therapeutics, Inc.
- Study site
- Yale Cancer Center
- Registry record
- NCT07029399 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in New Haven, CT on ClinicalTrials.gov.
Lung cancer studies recruiting in New Haven
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Yale University
- Registry record
- NCT06287775 · updated
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Smilow Cancer Center at Yale-New Haven ( Site 3253)
- Registry record
- NCT07513376 · updated
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- BioNTech SE
- Study site
- Yale University
- Registry record
- NCT07111520 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Yale University
- Registry record
- NCT04267848 · updated
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- SystImmune Inc.
- Study site
- Yale Cancer Center
- Registry record
- NCT07080242 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Yale University School of Medicine ( Site 0201)
- Registry record
- NCT06623422 · updated
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Yale Cancer Center
- Registry record
- NCT05789082 · updated
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- Smilow Cancer Hospital - Yale New Haven Health · Smilow Cancer Hospital Phase 1 Unit · Yale - New Haven Hospital - Yale Cancer Center
- Registry record
- NCT07090499 · updated
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- Smilow Cancer Hospital - Yale New Haven Health · Smilow Cancer Hospital Phase 1 Unit · Yale - New Haven Hospital - Yale Cancer Center
- Registry record
- NCT07519655 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in New Haven, CT on ClinicalTrials.gov.
Prostate cancer studies recruiting in New Haven
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Yale-New Haven Hospital-Yale Cancer Center ( Site 0064)
- Registry record
- NCT06136624 · updated
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
- Phase 1/2
- Ages 18 and older
- Male participants
- Sponsor
- Genentech, Inc.
- Study site
- Yale Cancer Center
- Registry record
- NCT07567846 · updated
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Yale University Hospital
- Registry record
- NCT03972657 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in New Haven, CT on ClinicalTrials.gov.
Melanoma studies recruiting in New Haven
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Yale Cancer Center
- Registry record
- NCT06246916 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in New Haven, CT on ClinicalTrials.gov.
Lymphoma studies recruiting in New Haven
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Yale University
- Registry record
- NCT05272384 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Yale University
- Registry record
- NCT05675410 · updated
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Yale University
- Registry record
- NCT06649812 · updated
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Yale Cancer Center
- Registry record
- NCT06084936 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in New Haven, CT on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in New Haven
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Yale University
- Registry record
- NCT07621718 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in New Haven, CT on ClinicalTrials.gov.
Ask about studies near New Haven
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections